Literature DB >> 6286766

Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes.

D D Ma, T A Sylwestrowicz, S Granger, M Massaia, R Franks, G Janossy, A V Hoffbrand.   

Abstract

Terminal deoxynucleotidyl transferase (TdT) and purine metabolic enzymes were examined in subsets of human infant thymocytes (defined by surface cell antigens) and normal peripheral T lymphocytes. Putative prothymocytes (RFB-1+, HTA-1+/- large blast-like cells), medium and high density cortical thymocytes (RFB-1+, HTA-1+), and medullary thymocytes (RFB-1-, HTA-1-, OKT3+) were isolated by density gradient centrifugation, monoclonal antibody and complement-mediated cytolysis, and cell-antibody affinity chromatography. Peripheral T lymphocytes were isolated from normal adult mononuclear cells using nylon fiber technique. Adenosine deaminase (ADA) and TdT were highest in prothymocytes 48.8 +/- 14.7 mumol/hr/10(8) cells (mean +/- SE) and 22.9 +/- 1.4 U/10(8) cells, respectively. Both enzymes decreased progressively down the maturation pathway. In peripheral T lymphocytes, ADA was 3.9 +/- 1.5 mumol/hr/10(8) cells, and TdT was undetectable. Purine nucleoside phosphorylase (PNP) and ecto-5'nucleotidase (5'NT) were lowest in cortical thymocytes (27.5 +/- 11.0 nmol/hr/10(6) cells and 2.8 +/- 1.3 nmol/hr/10(6) cells, respectively) and increased with T cell maturation. The PNP level was 124.9 +/- 17.2 nmol/hr/10(6) cells and 5'NT was 30.1 +/- 3.9 nmol/hr/10(6) cells in peripheral T lymphocytes. The deoxynucleoside kinases (deoxyguanosine, deoxyadenosine, and deoxycytidine kinases) paralleled the changes in ADA and TdT activity among the different T subsets. The proliferative activity (labeling index) was highest in the prothymocyte fraction and lowest in peripheral T cells. Variation in the distribution of these enzymes in T cell subsets may explain their different sensitivities to deoxyadenosine and deoxyguanosine toxicity and the different effects on T cell development of ADA or PNP deficiency.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73).

Authors:  R Resta; S W Hooker; A B Laurent; S M Jamshedur Rahman; M Franklin; T B Knudsen; N L Nadon; L F Thompson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Surface expression of adenosine deaminase in mitogen-stimulated lymphocytes.

Authors:  M Martin; J J Centelles; J Huguet; F Echevarne; D Colomer; J L Vives-Corrons; R Franco
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

Review 3.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

4.  Patterns of adenosine deaminase, ecto-5'-nucleotidase, poly(A)polymerase and surface light chain expression in chronic lymphocytic leukemias.

Authors:  T Trangas; N Courtis; A Gounaris; S Perez; D Kokkinopoulos; G A Pangalis; C M Tsiapalis
Journal:  Blut       Date:  1989-04

Review 5.  Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.

Authors:  A D Ho; K Ganeshaguru
Journal:  Klin Wochenschr       Date:  1988-06-01

6.  Biochemical and immunological differentiation of human thymocytes induced by thymic hormones.

Authors:  A D Ho; D D Ma; G Price; W Hunstein; A V Hoffbrand
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

7.  Effect of thymosin on glucocorticoid receptor activity and glucocorticoid sensitivity of human thymocytes.

Authors:  D D Ma; A H Ho; A V Hoffbrand
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

8.  Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections.

Authors:  I Tsuboi; K Sagawa; S Shichijo; M M Yokoyama; D W Ou; M D Wiederhold
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Development and maintenance of bovine cytotoxic lymphocytes with recombinant human interleukin-2.

Authors:  J Carter; N S Magnuson; W C Davis; P H Mason; J A Magnuson; J E Talmadge; P J Barr
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

10.  Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.

Authors:  Michelle L Joachims; Patrick A Marble; Aletha B Laurent; Peter Pastuszko; Marco Paliotta; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.